Advice

following a full submission assessed under the orphan equivalent medicine process:

levodopa 20mg/mL + carbidopa monohydrate 5mg/mL + entacapone 20mg/mL intestinal gel (Lecigon®) is not recommended for use within NHSScotland.

Indication under review: treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.

In a phase I pharmacokinetic study, in patients with advanced levodopa-responsive Parkinson's disease, dose-adjusted levodopa exposure was significantly higher with Lecigon® treatment, when compared with levodopa / carbidopa monohydrate intestinal gel.

The submitting company did not present a sufficiently robust clinical or economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
levodopa/carbidopa/entacapone (Lecigon)
SMC ID:
SMC2507
Indication:

For treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results

Pharmaceutical company
Britannia Pharmaceuticals Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Not recommended
Date advice published
09 December 2024